W P Bowman
St. Jude Children's Research Hospital
26 Papers
599 Citations
W P Bowman is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Leukemia & Vincristine. The author has an hindex of 19, co-authored 26 publications. Previous affiliations of W P Bowman include Institut Gustave Roussy & French Institute of Health and Medical Research.
Chat about Author
Papers
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
Kirk R. Schultz,Andrew J. Carroll,Nyla A. Heerema,W P Bowman,Alexander Aledo,William B. Slayton,H N Sather,Meenakshi Devidas,H. W. Zheng,Stella M. Davies,Paul S. Gaynon,Michael E. Trigg,Robert Rutledge,Dean Thomas Jorstad,Naomi J. Winick,Michael J. Borowitz,Stephen P. Hunger,William L. Carroll,Bruce M. Camitta +18 more
TL;DR: Longer-term follow-up confirms the initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.
431
Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.
Naomi J. Winick,R W McKenna,Jonathan J. Shuster,Nancy R. Schneider,Michael J. Borowitz,W P Bowman,D. Jacaruso,Barton A. Kamen,George R. Buchanan +8 more
TL;DR: This experience provides strong evidence for a link between epipodophyllotoxin therapy and secondary AML since none of these children received alkylating agent therapy or irradiation.
269
Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia
Dorothy L. Williams,Anastasios Tsiatis,Garrett M. Brodeur,A T Look,Susan L. Melvin,W P Bowman,David K. Kalwinsky,Gaston K. Rivera,Gary V. Dahl +8 more
TL;DR: Results of a multivariate analysis indicated that chromosome number was the strongest single predictor of outcome and was the only variable that added significant prognostic information to leukocyte count (p less than 0.001) and should more clearly distinguish patients with ALL at low or high risk of relapse.
233
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
Jun J. Yang,Cheng Cheng,Wenjian Yang,Deqing Pei,Xueyuan Cao,Yiping Fan,Stanley Pounds,Geoffrey Neale,Lisa R. Treviño,Deborah L. French,Dario Campana,James R. Downing,William E. Evans,Ching-Hon Pui,Meenakshi Devidas,W P Bowman,Bruce M. Camitta,Cheryl L. Willman,Stella M. Davies,Michael J. Borowitz,William L. Carroll,Stephen P. Hunger,Mary V. Relling +22 more
TL;DR: Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.
233
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
Deepa Bhojwani,Deqing Pei,John T. Sandlund,John T. Sandlund,Sima Jeha,Sima Jeha,Raul C. Ribeiro,Raul C. Ribeiro,Jeffrey E. Rubnitz,Jeffrey E. Rubnitz,Susana C. Raimondi,S. A. Shurtleff,Mihaela Onciu,C. Cheng,Elaine Coustan-Smith,W P Bowman,Scott C. Howard,Scott C. Howard,Monika L. Metzger,Monika L. Metzger,Hiroto Inaba,Hiroto Inaba,Wing Leung,Wing Leung,William E. Evans,William E. Evans,Dario Campana,Dario Campana,Mary V. Relling,Mary V. Relling,C H Pui,C H Pui +31 more
TL;DR: The MRD-guided treatment schema including intensive asparaginase and high-dose methotrexate in the Total XV study produced significantly better outcomes than previous regimens and demonstrated that nearly all children with ETV6-RUNX1 ALL can be cured.
138